JFC - Jülich Fine Chemicals and Prokaria enter into strategic partnership on new enzymes for asymmetric reduction
Advertisement
JFC - Jülich fine chemicals GmbH and Prokaria ehf today announced the signing of a partnership agreement. This strategic move brings together one of the world´s most diverse extreme ecosystems and the most interesting growth segment of chiral selective biosynthesis.
Under the terms of the agreement the partners will commence a screening and de-velopment program for novel biocatalysts to synthesize chiral alcohols. These mole-cules are key components, used to produce active pharmaceutical ingredients (APIs) and hence play an important role in innovations in fine chemistry and pharma. The endeavor is well supported by the competence of the partners. While Prokaria plays a home match in identifying novel enzymes in the biosphere of arctic areas and hotsprings of Iceland, JFC is a well established production and marketing company in the fine chemistry industry.
"This is one of the most exciting opportunities in the history of our company" says Prof. Jakob Kristjánsson, President and CEO of Prokaria. "Positioning, competencies and size of JFC are an excellent complementation of our own assets and we have hopes to attract the attention of important customers soon."
In Jülich, Dr. Thomas Daußmann, CEO of Jülich Fine Chemicals, commented: "The alliance with Prokaria adds a new growth potential to our business. The new bio-catalysts we seek to develop belong to the most wanted components in the branch."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Merck Collaborates with Innovative Biotech to Support Establishment of First Vaccine Production Facility in Nigeria
Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"
Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe
Risk of lead poisoning from urban gardening is low, new study finds
World first: Launch of Quebec registry for users of medical cannabis - MUHC researcher heads one of the largest studies ever conducted on medical cannabis
Implant-based cancer vaccine is first to eliminate tumors in mice - New approach reprograms the mammalian immune system to attack tumors body-wide
Study IDs link between sugar signaling and regulation of oil production in plants
It all adds up: Study finds forever chemicals are more toxic as mixtures - Research also finds that PFOA and PFOS are major contributors to toxicity
Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
‘Seaweed drug’ helps fight off infection - Alginates found in seaweed can combat multi-drug resistant infections
Antibiotic-releasing polymer may help eradicate joint implant infection
